Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection With Sumatriptan Succinate Using an Auto-injector During a Single Migraine Attack

NCT00510419 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00510419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection With Sumatriptan Succinate Using an Auto-injector During a Single Migraine Attack
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
December 31, 2007
Enrollment
73 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

migraine